

Statement of unaudited financial results for the quarter and half year ended 30 September, 2020

(₹ in Millions)

Particulars (Refer notes below)	Standalone (Ind AS)						Consolidated (Ind AS)					
	Quarter Ended 30-09-2020 (Unaudited)	Quarter Ended 30-06-2020 (Unaudited)	Quarter Ended 30-09-2019 (Unaudited)	Half Year Ended 30-09-2020 (Unaudited)	Half Year Ended 30-09-2019 (Unaudited)	Year Ended 31-03-2020 (Audited)	Quarter Ended 30-09-2020 (Unaudited)	Quarter Ended 30-06-2020 (Unaudited)	Quarter Ended 30-09-2019 (Unaudited)	Half Year Ended 30-09-2020 (Unaudited)	Half Year Ended 30-09-2019 (Unaudited)	Year Ended 31-03-2020 (Audited)
I Revenue from operations	20,254.92	16,524.45	17,426.23	36,779.37	31,978.56	64,912.00	29,081.18	23,092.83	27,637.31	52,174.01	50,473.35	103,972.28
(a) Net sales	366.73	304.77	471.96	671.50	907.56	2,214.31	443.61	355.04	513.09	798.65	905.84	2,437.41
(b) Other operating income	20,621.65	16,829.22	17,898.19	37,450.87	32,886.12	67,126.31	29,524.79	23,447.87	28,150.40	52,972.66	51,379.19	106,409.69
II Total revenue from operations	634.04	1,348.49	1,924.68	1,982.53	2,610.09	6,067.88	(318.81)	585.14	808.25	266.33	824.94	1,596.02
III Total income (I + II)	21,255.69	18,177.71	19,822.87	39,433.40	35,496.21	73,194.19	29,205.98	24,033.01	28,958.65	53,238.99	52,204.13	108,005.71
IV Expenses	7,503.36	5,917.41	5,675.87	13,420.77	10,869.60	22,519.81	8,648.40	7,041.92	6,466.53	15,690.32	12,552.58	25,414.74
(a) Cost of materials consumed	658.51	762.73	928.73	1,421.24	1,894.86	3,652.41	2,976.78	217.83	2,788.10	3,194.61	5,375.10	10,290.83
(b) Purchases of stock-in-trade	41.63	(157.24)	196.85	(115.61)	104.01	487.68	(1,218.03)	823.91	606.86	(394.12)	34.83	1,280.82
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	3,375.76	2,372.36	3,457.94	5,748.12	5,658.10	10,723.27	7,002.54	5,096.06	6,866.00	12,098.60	11,732.90	22,547.76
(d) Employee benefits expense	604.12	599.38	651.67	1,203.50	1,332.43	2,563.90	806.32	937.40	897.71	1,743.72	1,827.86	3,773.18
(e) Finance costs	367.94	358.09	333.22	726.03	654.87	1,385.38	1,040.65	1,132.22	941.61	2,172.87	1,848.92	4,171.66
(f) Depreciation, amortisation and impairment expense	4,088.84	2,846.52	3,833.52	6,935.36	7,467.83	16,700.84	6,586.97	5,487.47	6,918.83	12,074.44	13,760.58	29,894.72
(g) Other expenses	16,640.16	12,699.25	15,077.80	29,339.41	27,981.70	58,033.29	25,843.63	20,736.81	25,485.64	46,580.44	47,132.77	97,373.71
Total expenses (IV)	4,615.53	5,478.46	4,745.07	10,093.99	7,514.51	15,160.90	3,362.35	3,296.20	3,473.01	6,658.55	5,071.36	10,632.00
V Profit/(loss) before exceptional items and tax (III - IV)	0.00	(279.90)	-	(279.90)	-	(185.54)	(31.40)	(279.90)	-	(311.30)	-	(328.76)
VI Exceptional items (gain) (Refer note 6)	4,615.53	5,758.36	4,745.07	10,373.89	7,514.51	15,346.44	3,393.75	3,576.10	3,473.01	6,969.85	5,071.36	10,960.76
VII Profit/(loss) before tax (V - VI)	-	-	-	-	-	-	-	-	-	-	-	-
VIII Tax expense:	802.53	1,012.33	713.19	1,814.86	1,317.96	2,692.37	1,367.28	1,322.78	1,030.15	2,690.06	1,989.77	3,961.27
Current tax	(215.76)	(121.28)	(288.04)	(94.48)	(891.41)	(313.46)	(287.10)	(287.10)	(112.56)	(600.56)	(566.64)	(760.21)
IX Profit/(loss) for the period from continuing operations (VII - VIII)	4,028.76	4,624.75	4,319.92	8,653.51	6,598.35	13,545.48	2,339.93	2,540.42	2,555.42	4,880.35	3,648.23	7,759.70
X Profit/(loss) before tax from discontinuing operations	-	-	-	-	-	-	-	-	-	-	-	-
XI Tax expense of discontinuing operations:	-	-	-	-	-	-	-	-	-	-	-	-
Current tax	-	-	-	-	-	-	-	-	-	-	-	-
Deferred tax	-	-	-	-	-	-	-	-	-	-	-	-
XII Profit/(loss) for the period from discontinuing operations (X - XI)	-	-	-	-	-	-	-	-	-	-	-	-
XIII Profit/(loss) for the period for continuing and discontinuing operations (IX + XII)	4,028.76	4,624.75	4,319.92	8,653.51	6,598.35	13,545.48	2,339.93	2,540.42	2,555.42	4,880.35	3,648.23	7,759.70
XIV Other comprehensive income	5.44	5.51	(43.72)	10.95	(25.69)	(88.83)	(137.89)	0.37	(164.35)	(137.52)	(202.60)	52.52
A (i) Items that will not be reclassified to profit or loss	(1.90)	(1.93)	14.04	(3.83)	8.47	34.61	15.72	(0.38)	29.86	15.34	31.08	15.08
(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-	(291.15)	259.62	(947.49)	(31.53)	(535.39)	(2,248.33)
B (i) Items that will be reclassified to profit or loss	-	-	-	-	-	-	215.22	(16.32)	(81.50)	198.90	(56.51)	(276.42)
(ii) Income tax relating to items that will be reclassified to profit or loss	4,032.30	4,628.33	4,290.24	8,660.63	6,581.13	13,491.26	2,141.83	2,783.71	1,391.94	4,925.54	2,884.81	5,302.55
XV Total comprehensive income	4,032.30	4,628.33	4,290.24	8,660.63	6,581.13	13,491.26	2,142.26	2,782.38	1,391.47	4,924.64	2,884.06	60,422.88
XVI Total comprehensive income attributable to:	-	-	-	-	-	-	(0.43)	1.33	0.47	0.90	0.75	0.03
- Non-controlling interests	-	-	-	-	-	-	-	-	-	-	-	-
- Owners of the Company	4,032.30	4,628.33	4,290.24	8,660.63	6,581.13	13,491.26	2,142.26	2,782.38	1,391.47	4,924.64	2,884.06	60,422.88
XVII Other equity	-	-	-	-	-	-	-	-	-	-	-	-
XVIII Earning per share (EPS) (for continuing operations) (of Re 1/- each) (not annualised)*	14.28	16.39	15.31	30.67	23.38	48.00	8.29	9.00	9.06	17.30	12.93	27.50
Basic EPS (in Rupees)	14.28	16.39	15.31	30.67	23.38	48.00	8.29	9.00	9.06	17.30	12.93	27.50
Diluted EPS (in Rupees)	-	-	-	-	-	-	-	-	-	-	-	-
XIX Earning per share (EPS) (for discontinuing operations) (of Re 1/- each) (not annualised)*	-	-	-	-	-	-	-	-	-	-	-	-
Basic EPS (in Rupees)	-	-	-	-	-	-	-	-	-	-	-	-
Diluted EPS (in Rupees)	-	-	-	-	-	-	-	-	-	-	-	-
XX Earning per share (EPS) (for continuing and discontinuing operations) (of Re 1/- each) (not annualised)*	14.28	16.39	15.31	30.67	23.38	48.00	8.29	9.00	9.06	17.30	12.93	27.50
Basic EPS (in Rupees)	14.28	16.39	15.31	30.67	23.38	48.00	8.29	9.00	9.06	17.30	12.93	27.50
Diluted EPS (in Rupees)	-	-	-	-	-	-	-	-	-	-	-	-

* except for the year ended 31 March 2020

Glenmark Pharmaceuticals Limited Statement of assets and liabilities (All amounts in million of Indian Rupees, unless otherwise stated)

Particulars	STANDALONE		CONSOLIDATED	
	Ind AS As at 30.09.2020 Unaudited	Ind AS As at 31.03.2020 Audited	Ind AS As at 30.09.2020 Unaudited	Ind AS As at 31.03.2020 Audited
ASSETS				
Non current assets				
Property, plant and equipment	14,817.15	14,688.16	29,453.85	29,777.08
Capital work-in-progress	1,042.78	1,524.97	11,280.58	10,906.36
Goodwill	-	-	558.20	528.99
Other intangible assets	1,353.05	1,431.29	21,074.40	19,979.48
Intangible assets under development	1,468.05	475.17	1,681.87	1,312.50
Financial assets				
(i) Investments	47,249.23	47,139.29	246.00	245.91
(ii) Loans	76,617.02	71,155.46	-	-
(iii) Other financial assets	333.65	268.80	713.63	655.79
Deferred tax assets (net)	8,138.00	8,047.35	15,022.68	14,557.05
Other non-current assets	525.78	546.53	1,081.32	848.75
Total non-current assets	151,544.71	145,277.02	81,112.53	78,811.91
Current assets				
Inventories	8,097.11	8,375.02	22,025.01	21,356.24
Financial assets				
(i) Investments	-	-	-	-
(ii) Trade receivables	20,454.24	18,352.40	26,479.90	24,089.62
(iii) Cash and cash equivalents	419.78	872.92	8,872.94	11,102.75
(iv) Bank balance other than cash and cash equivalents	8.24	9.67	8.24	9.67
(v) Other financial assets	10,747.91	11,191.99	1,398.12	1,249.44
Current tax assets	5,872.05	5,436.97	11,018.42	10,228.44
Other current assets	45,599.33	44,238.97	69,802.63	68,036.16
Total current assets	197,144.04	189,515.99	150,915.16	146,848.07
EQUITY AND LIABILITIES				
Equity				
Equity share capital	282.17	282.17	282.17	282.17
Other equity	139,963.50	131,980.47	64,670.03	60,422.88
Non-controlling interests	-	-	(3.11)	(3.92)
Liabilities				
Non-current liabilities				
Financial liabilities				
(i) Borrowings	16,542.04	31,311.66	25,959.00	40,429.94
(ii) Other financial liabilities	1,960.20	2,056.51	4,332.44	4,288.01
Deferred tax liabilities (net)	-	-	196.82	164.48
Other non-current liabilities	-	-	7.76	4.68
Total non-current liabilities	18,502.24	33,368.17	30,496.02	44,887.11
Current liabilities				
Financial liabilities				
(i) Borrowings	3,627.16	4,425.97	3,627.16	4,425.97
(ii) Other financial liabilities	16,490.56	2,035.95	21,317.17	8,583.66
(iii) Trade payables	-	-	-	-
- Total outstanding dues of Micro enterprises and Small enterprises	621.01	748.82	804.19	849.48
- Total outstanding dues of other than Micro enterprises and Small enterprises	14,869.55	15,107.11	20,866.53	20,408.95
Other current liabilities	282.67	388.25	1,191.80	1,432.65
Provisions	1,769.42	1,024.04	6,491.32	5,151.99
Current tax liabilities (net)	798.49	160.44	1,171.88	407.13
Total current liabilities	38,396.13	23,885.18	55,470.05	41,259.83
Total liabilities	56,898.37	57,253.35	85,966.07	86,146.94
Total equity and liabilities	197,144.04	189,515.99	150,915.16	146,848.07

Glenmark Pharmaceuticals Limited Consolidated statement of cash flows for the half year ended 30 September, 2020 (All amounts in million of Indian Rupees, unless otherwise stated)

Particulars	Half Year Ended 30-09-2020 (Unaudited)	Half Year Ended 30-09-2019 (Unaudited)
	(A) Cash flow from operating activities	
Profit before tax	6,969.85	5,071.37
Adjustments to reconcile profit before tax to net cash provided by operating activities:		
Depreciation, impairment and amortisation	2,172.87	1,848.92
Finance costs	1,743.72	1,827.86
Interest income	(9.70)	(27.76)
(Profit)/loss on sale of property, plant and equipments	26.18	(1.13)
Fair valuation of Investment	(0.09)	-
Employee benefit obligation	407.59	197.96
Provision for doubtful debts / expected credit losses	0.09	100.14
Employee share based compensation expense	27.81	22.37
Exceptional item	(311.30)	-
Unrealised foreign exchange (gain)	(245.89)	(208.32)
Operating profit before working capital changes	10,781.13	8,831.41
Changes in operating assets and liabilities		
- (Increase)/ Decrease in trade receivables	(2,334.88)	869.82
- (Increase) / Decrease in inventories	(321.72)	800.66
- (Increase)/ Decrease in other assets	(1,402.41)	(816.83)
- Increase/(Decrease) in trade payable and other liabilities	(537.85)	(1,728.63)
Cash generated from operations	6,184.27	7,956.43
Income taxes paid	(1,945.27)	(2,089.47)
Net cash generated from operating activities	4,239.00	5,866.96
(B) Cash flow from investing activities		
(Increase)/ Decrease in restricted cash	1.39	707.74
Interest received	13.90	29.32
Payments for Purchase of Property, plant and equipment and Intangible assets (including Capital work in		

